Savara Inc.
NASDAQSVRA heads into its November 11 earnings date with a contradictory setup: a fresh JP Morgan buy-side initiation at $12 landed this morning, yet shorts have been building for six weeks straight and the stock has shed 13% over the past month to close at $4.65. The positioning tells a cautious story for the lending market, though not an extreme one. Short interest has climbed to 21.6%…
Snapshot as of 7 Oct 2026
SVRA heads into its November 11 earnings date with a contradictory setup: a fresh JP Morgan buy-side initiation at $12 landed this morning, yet shorts have been building for six weeks straight and the stock has shed…
SVRA reports August 12 results as the stock trades at $5.57 — down 8% over the past month but recovering modestly over the past week — with short sellers holding one of the largest positions in small-cap biotech. Short…
Savara Inc. has now cleared its May 20 earnings event — and shorts haven't blinked. Short interest is essentially unchanged at 13.6% of the free float, flat on the week and up roughly 3% over the past month. That level…
SVRA heads into its May 20 earnings report with a striking split between an unusually bullish options signal and a short interest load that remains one of the heaviest in small-cap biotech. The options market just…
Savara Inc. walks into tonight's earnings with one of the more heavily shorted profiles in small-cap biotech, and bears have been adding to that position all month. Short interest is running at 13.5% of the free float…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SVRA — free to start on ORTEX.
Sign up for free →Open SVRA on ORTEX